Clinical trial · Observational
Anti-tumor Specific Immune Response in Head and Neck Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head \& Neck Squamous Cell Carcinoma Secondary purposes are: * Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs); * Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS * Study of relationship between anti-tumor immune response and clinical stage as well as DFS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- squamous cell carcinoma
- description
- Patients affected by Head \& Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
- interventionNames
- Other: Blood sample
Primary outcomes (1)
- measure
- Presence or absence of spontaneous responses against tumor-associated antigens (TAA) according to tumor stage
- timeFrame
- day 0
Secondary outcomes (5)
- measure
- Functional signature of T cell responses (polyfunctionality index of lymphocytes) according to tumor stage
- timeFrame
- day 0
- description
- Effector functions and phenotypes of T cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with Head \& Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy) * Consent to participate to the study, non-opposition * Affiliation to social security Exclusion Criteria: * History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy * HIV infection * Corticotherapy during 15 days before blood sampling
References
Publications (0)
Data not yet available